# TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

> **NCT04104139** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Rectal Adenocarcinoma
- Stage IIA Rectal Cancer AJCC v8
- Stage IIB Rectal Cancer AJCC v8
- Stage III Rectal Cancer AJCC v8
- Stage IIIA Rectal Cancer AJCC v8
- Stage IIIB Rectal Cancer AJCC v8
- Stage IIIC Rectal Cancer AJCC v8

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Trifluridine and Tipiracil Hydrochloride

## Key facts

- **NCT ID:** NCT04104139
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-11
- **Primary completion:** 2024-09-25
- **Final completion:** 2026-05-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- Oregon Health and Science University
- Taiho Pharmaceutical Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104139, "TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04104139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*